Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Arcutis Biotherapeutics	Zealand Pharma A/S	Applied Molecular Transport	Olema Pharmaceuticals	Cara Therapeutics
Symbol	NASDAQ:ARQT	NASDAQ:ZEAL	NASDAQ:AMTI	NASDAQ:OLMA	NASDAQ:CARA
Price Information
Current Price	$25.75	$29.00	$44.70	$25.11	$13.20
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.6	1.2	2.0	1.6	1.8
Analysis Score	3.5	3.5	3.5	3.5	3.5
Community Score	2.2	2.5	3.6	4.3	3.1
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	0.0	2.5	0.0	1.7
Earnings & Valuation Score	0.6	0.0	0.6	0.0	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$54.67	$43.00	$68.75	$60.67	$32.00
% Upside from Price Target	112.30% upside	48.28% upside	53.80% upside	141.60% upside	142.42% upside
Trade Information
Market Cap	$1.29 billion	$1.26 billion	$1.58 billion	$1.01 billion	$660.69 million
Beta	N/A	1.19	N/A	N/A	1.7
Average Volume	265,427	11,822	227,360	152,316	1,051,990
Sales & Book Value
Annual Revenue	N/A	$6.20 million	N/A	N/A	$19.89 million
Price / Sales	N/A	203.23	N/A	N/A	33.22
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	N/A	$5.85 per share	N/A	N/A	$4.66 per share
Price / Book	N/A	4.96	N/A	N/A	2.83
Profitability
Net Income	$-42,000,000.00	$-85,670,000.00	$-28,040,000.00	N/A	$-106,370,000.00
EPS	($22.78)	($2.54)	N/A	N/A	($2.49)
Trailing P/E Ratio	N/A	N/A	0.00	0.00	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	-214.31%	N/A	N/A	-360.35%
Return on Equity (ROE)	-81.74%	-38.34%	N/A	N/A	-64.36%
Return on Assets (ROA)	-57.72%	-30.40%	N/A	N/A	-53.22%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	N/A	N/A	N/A
Current Ratio	9.18%	6.76%	19.39%	N/A	8.00%
Quick Ratio	9.18%	6.51%	19.39%	N/A	8.00%
Ownership Information
Institutional Ownership Percentage	79.63%	4.32%	51.99%	N/A	67.01%
Insider Ownership Percentage	N/A	N/A	N/A	N/A	5.70%
Miscellaneous
Employees	54	329	80	36	80
Shares Outstanding	50.21 million	43.45 million	35.25 million	40.17 million	50.05 million
Next Earnings Date	8/10/2021 (Estimated)	8/12/2021 (Estimated)	8/10/2021 (Estimated)	8/10/2021 (Estimated)	8/9/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Not Optionable	Not Optionable	Optionable

Source	Headline
	Cara Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation seekingalpha.com - May 13 at 4:50 PM
	Jefferies Financial Group Analysts Raise Earnings Estimates for Cara Therapeutics, Inc. (NASDAQ:CARA) americanbankingnews.com - May 13 at 10:44 AM
	Piper Sandler Analysts Boost Earnings Estimates for Cara Therapeutics, Inc. (NASDAQ:CARA) americanbankingnews.com - May 13 at 9:30 AM
	Cara Therapeutics EPS beats by $0.12, misses on revenue seekingalpha.com - May 12 at 11:10 PM
	Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q1 2021 Results - Earnings Call Transcript seekingalpha.com - May 12 at 6:09 PM
	Piper Sandler Weighs in on Cara Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:CARA) americanbankingnews.com - May 12 at 7:56 AM
	Cara Therapeutics (NASDAQ:CARA) Announces Quarterly Earnings Results americanbankingnews.com - May 11 at 3:38 PM
	Cara Therapeutics Inc (CARA) Q1 2021 Earnings Call Transcript finance.yahoo.com - May 11 at 12:49 AM
	Cara: Q1 Earnings Snapshot sfgate.com - May 10 at 7:48 PM
	BRIEF-Cara Therapeutics Reports Q1 Loss Per Share $0.47 msn.com - May 10 at 7:48 PM
	Cara Therapeutics: Q1 Earnings Insights benzinga.com - May 10 at 7:48 PM
	Cara Therapeutics Reports First Quarter 2021 Financial Results finance.yahoo.com - May 10 at 7:48 PM
	Cara Therapeutics (CARA) Reports Q1 Loss, Misses Revenue Estimates finance.yahoo.com - May 10 at 7:48 PM
	Cara Therapeutics (NASDAQ:CARA) Reaches New 1-Year Low at $12.16 americanbankingnews.com - May 10 at 4:14 PM
	Cara Therapeutics Inc. (NASDAQ:CARA) Climbs 107% In 2021; Is It Attractive Enough At $12.56? marketingsentinel.com - May 8 at 7:31 PM
	FY2022 Earnings Forecast for Cara Therapeutics, Inc. (NASDAQ:CARA) Issued By Cantor Fitzgerald americanbankingnews.com - May 7 at 9:24 AM
	Cara Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference finance.yahoo.com - May 6 at 6:33 PM
	Here is a bargain stock you should look at : Cara Therapeutics Inc. (CARA) marketingsentinel.com - May 5 at 5:32 PM
	Needham & Company LLC Lowers Cara Therapeutics (NASDAQ:CARA) Price Target to $26.00 americanbankingnews.com - May 5 at 3:27 PM
	Cara Therapeutics (NASDAQ:CARA) Hits New 1-Year Low at $12.26 americanbankingnews.com - May 4 at 9:02 PM
	Cara Therapeutics (CARA) to Release Earnings on Monday americanbankingnews.com - May 4 at 12:04 PM
	Cara Therapeutics (CARA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release finance.yahoo.com - May 3 at 7:53 PM
	Cara Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021 finance.yahoo.com - May 3 at 7:53 PM
	Short Interest in Cara Therapeutics, Inc. (NASDAQ:CARA) Expands By 30.7% americanbankingnews.com - May 3 at 1:08 AM
	Cara Therapeutics Inc. [CARA] Is Currently -45.44 below its 200 Period Moving Avg: What Dose This Mean? dbtnews.com - April 30 at 10:59 PM
	Cara Therapeutics (NASDAQ:CARA) Price Target Lowered to $26.00 at Needham & Company LLC marketbeat.com - April 29 at 2:09 PM

Date	Company	Brokerage	Action
2/2/2021	Arcutis Biotherapeutics	Truist	Boost Price Target
2/1/2021	Arcutis Biotherapeutics	Cowen	Boost Price Target
1/28/2021	Arcutis Biotherapeutics	Jonestrading	Initiated Coverage
11/9/2020	Arcutis Biotherapeutics	The Goldman Sachs Group	Upgrade
3/20/2020	Arcutis Biotherapeutics	Cantor Fitzgerald	Reiterated Rating
2/25/2020	Arcutis Biotherapeutics	Guggenheim	Initiated Coverage
11/13/2020	Zealand Pharma A/S	Morgan Stanley	Lower Price Target
8/13/2020	Zealand Pharma A/S	Needham & Company LLC	Initiated Coverage
11/27/2019	Zealand Pharma A/S	Jefferies Financial Group	Downgrade
3/23/2021	Applied Molecular Transport	JMP Securities	Initiated Coverage
2/25/2021	Applied Molecular Transport	SVB Leerink	Boost Price Target
6/30/2020	Applied Molecular Transport	Bank of America	Initiated Coverage
12/14/2020	Olema Pharmaceuticals	JPMorgan Chase & Co.	Initiated Coverage
12/14/2020	Olema Pharmaceuticals	Canaccord Genuity	Initiated Coverage
4/21/2020	Cara Therapeutics	HC Wainwright	Boost Price Target
7/30/2019	Cara Therapeutics	Piper Jaffray Companies	Boost Price Target
5/29/2019	Cara Therapeutics	Laidlaw	Boost Price Target

(Data available from 5/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources